Investigating Healthcare Disparities in Vitiligo

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39374 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-20

Study Completion Date

2024-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are however, limited population-based studies on the burden of vitiligo and disparities across people of different ethnicities and deprivation.

The overall purpose of this study is to provide an estimate of the lifetime risk of vitiligo in the population overall and by sociodemographic subgroups. Moreover, to do a subgroup analysis in the vitiligo population to identify health-related disparities across people in different sex, age, deprivation and ethnicity. A detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Translational Assessment of Vitiligo According to Body Locations

NCT06068218

Vitiligo

ACTIVE_NOT_RECRUITING NA

Vitiligo Registry for Adults and Children in the UK

NCT06218082

Dermatologic Disease Vitiligo

NOT_YET_RECRUITING

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

NCT07058051

Non-Segmental Vitiligo

COMPLETED

Histochemical Study of Vitiligo in Sohag University Hospital Patients

NCT05869942

Vitiligo

UNKNOWN NA

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

NCT03976622

Vitiligo Psoriasis Alopecia Areata +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will provide estimate of the cumulative lifetime risk of vitiligo in the population overall, and by important sociodemographic groups, including age, sex, ethnicity and deprivation, which will prevalent key data to show the relative burden of vitiligo across the aforementioned groups. These approaches allow creation of cumulative lifetime risk plots which provide an excellent and accessible way to display the relative disease burden across groups.

The cumulative lifetime risk of vitiligo will be estimated at age 80 years (approximate lifetime expectancy in the UK) using survival models, with age as the timescale and accounting for competing risk of death.

This study will also perform a subgroup analysis in the vitiligo population to identify health-related disparities across people in different deprivation, sex and ethnic groups. The disparities that will be considered are: Mental health conditions; healthcare utilisation; and work impact (time off work and unemployment),

The assessment of any associations with baseline characteristics and the outcome of interest will be used using Cox proportional hazards models (time to event outcomes) and generalised linear models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

People with Vitiligo

Children and adults with new onset Vitiligo registered with OPCRD during the study period.

No intervention

Intervention Type OTHER

Observational analysis of usual care only.

People without Vitiligo

Children and adults without Vitiligo registered with OPCRD during the study period

No intervention

Intervention Type OTHER

Observational analysis of usual care only.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Observational analysis of usual care only.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The cohort for the endpoint analysis will consist of all adults and adolescents (aged 13+) contributing to OPCRD during the study period (2004-2020).
* The cohort for the lifetime risk analysis will consist of all people contributing to OPCRD during the study period.
* The vitiligo cohort consists of people newly diagnosed with vitiligo at any point during the study period.

Exclusion Criteria

* People with the alternative non-vitiligo diagnoses (other hypopigmenting conditions).
* People with vitiligo diagnosis within 6 months of practice registration.
* People without vitiligo with less than 1 year of follow up within the dataset.
* People over the age of 95 (for those reaching age 95 during the follow up period follow up was censored at age 95).
* People who have opted out of record sharing.

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No